

Rami A Al-Horani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1986430/publications.pdf>

Version: 2024-02-01

42
papers

1,170
citations

361045

20
h-index

395343

33
g-index

46
all docs

46
docs citations

46
times ranked

1308
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemical sulfation of small moleculesâ€™ advances and challenges. <i>Tetrahedron</i> , 2010, 66, 2907-2918.	1.0	145
2	Sulfated Pentagalloylglucoside Is a Potent, Allosteric, and Selective Inhibitor of Factor XIa. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 867-878.	2.9	81
3	Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders. <i>Medicinal Research Reviews</i> , 2014, 34, 1168-1216.	5.0	65
4	Factor XIa inhibitors: A review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 323-345.	2.4	58
5	Recent advances in the discovery and development of factor XI/XIa inhibitors. <i>Medicinal Research Reviews</i> , 2018, 38, 1974-2023.	5.0	56
6	Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4805-4818.	2.9	49
7	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5224.	1.8	42
8	Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 195-203.	1.3	39
9	Discovery of Allosteric Modulators of Factor XIa by Targeting Hydrophobic Domains Adjacent to Its Heparin-Binding Site. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2415-2428.	2.9	38
10	Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 379-387.	0.8	38
11	Synthetic, Non-saccharide, Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells. <i>ACS Chemical Biology</i> , 2014, 9, 1826-1833.	1.6	37
12	Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 39-55.	2.4	35
13	Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. <i>Viruses</i> , 2020, 12, 1092.	1.5	34
14	Designing Nonsaccharide, Allosteric Activators of Antithrombin for Accelerated Inhibition of Factor Xa. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6125-6138.	2.9	33
15	Allosteric Partial Inhibition of Monomeric Proteases. Sulfated Coumarins Induce Regulation, not just Inhibition, of Thrombin. <i>Scientific Reports</i> , 2016, 6, 24043.	1.6	32
16	Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 641-657.	2.9	28
17	Inhibition of Herpes Simplex Virus-1 Entry into Human Cells by Nonsaccharide Glycosaminoglycan Mimetics. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 797-802.	1.3	27
18	Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 525-533.	1.0	23

#	ARTICLE	IF	CITATIONS
19	Plasmin Regulation through Allosteric, Sulfated, Small Molecules. <i>Molecules</i> , 2015, 20, 608-624.	1.7	22
20	A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2110-2122.	1.9	22
21	Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients. <i>Current Pharmaceutical Design</i> , 2021, 27, 866-875.	0.9	20
22	Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 12, 91-125.	0.4	20
23	Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 771-783.	2.6	19
24	Electronically rich N-substituted tetrahydroisoquinoline 3-carboxylic acid esters: concise synthesis and conformational studies. <i>Tetrahedron</i> , 2012, 68, 2027-2040.	1.0	19
25	Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile. <i>PLoS ONE</i> , 2016, 11, e0160189.	1.1	18
26	Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112442.	2.6	18
27	A small group of sulfated benzofurans induces steady-state submaximal inhibition of thrombin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1101-1105.	1.0	17
28	New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3013.	1.8	14
29	Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase. <i>ACS Omega</i> , 2021, 6, 12699-12710.	1.6	13
30	Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 15, 40-48.	0.4	13
31	The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis. <i>Molecules</i> , 2019, 24, 2146.	1.7	12
32	Discovery of Benzyl Tetrakisphosphate Derivative as Inhibitor of Human Factor XIa. <i>ChemistryOpen</i> , 2020, 9, 1161-1172.	0.9	12
33	Glycosaminoglycan-Protein Interaction Studies Using Fluorescence Spectroscopy. <i>Methods in Molecular Biology</i> , 2015, 1229, 335-353.	0.4	12
34	Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies. <i>Current Medicinal Chemistry</i> , 2020, 27, 3412-3447.	1.2	12
35	Synthesis of Glycosaminoglycan Mimetics Through Sulfation of Polyphenols. <i>Methods in Molecular Biology</i> , 2015, 1229, 49-67.	0.4	11
36	Targeting factor XI(a) for anticoagulation therapy: a patent landscape. <i>Pharmaceutical Patent Analyst</i> , 2020, 9, 3-5.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa. <i>Pharmaceuticals</i> , 2021, 14, 886.	1.7	8
38	Factor IX(a) inhibitors: an updated patent review (2003-present). <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 381-400.	2.4	7
39	Studies on fragment-based design of allosteric inhibitors of human factor XIa. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115762.	1.4	6
40	Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies. <i>Chemical Biology and Drug Design</i> , 2022, 100, 64-79.	1.5	6
41	395 Synthetic, Non-Saccharide Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells. <i>Gastroenterology</i> , 2014, 146, S-84-S-85.	0.6	0
42	Ethacrynic acid is an inhibitor of human factor XIIIa. <i>BMC Pharmacology & Toxicology</i> , 2022, 23, .	1.0	0